Skip to main content
. 2024 Dec 1;24(6):1785–1794. doi: 10.17305/bb.2024.10512

Figure 1.

Figure 1.

Kaplan–Meier progression-free survival estimate according to IMDC score (A); according to TKI response (long-term vs short-term) (B); in all patients. TKI: Tyrosine kinase inhibitor; IMDC: International Metastatic Renal Cell Carcinoma Database Consortium; PFS: Progression-free survival.